Newswire (Published: Monday, June 8, 2020, Received: Monday, June 8, 2020, 4:03:18 PM CDT)

Word Count: 372

2020 JUN 08 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Daily -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting out of Columbus, Ohio, by NewsRx editors, research stated, “Widespread cGMP-specific phosphodiesterase 5 (PDE5) inhibitor use in male reproductive health and particularly in prostate cancer patients following surgery has generated interest in how these drugs affect the ability of residual tumor cells to proliferate, migrate, and form recurrent colonies. Prostate cancer cell lines were treated with PDE5 inhibitors at clinically relevant concentrations.”

Financial supporters for this research include National Institutes of Health, Department of Defense Prostate Cancer Research Program.

Our news journalists obtained a quote from the research from the Ohio State University College of Medicine, “Proliferation, colony formation, and migration phenotypes remained stable even when cells were co-treated with a stimulator of cGMP synthesis that facilitated cGMP accumulation upon PDE5 inhibition. Surprisingly, supraclinical concentrations of PDE5 inhibitor counteracted proliferation, colony formation, and migration of prostate cancer cell models.”

According to the news editors, the research concluded: “These findings provide tumor cell-autonomous evidence in support of the field’s predominant view that PDE5 inhibitors are safe adjuvant agents to promote functional recovery of normal tissue after prostatectomy, but do not rule out potential cancer-promoting effects of PDE5 inhibitors in the more complex environment of the prostate.”

For more information on this research see: Prostate Cancer Cell Phenotypes Remain Stable Following PDE5 Inhibition in the Clinically Relevant Range. Translational Oncology, 2020;13(9):100797.

Our news journalists report that additional information may be obtained by contacting B. Sunkel, Dept. of Internal Medicine, Ohio State University College of Medicine, Columbus, OH 43210, United States. Additional authors for this research include W. Hankey, F. Yuan, H. He, J.M. Thomas-Ahner, Z. Chen, S.K. Clinton, J. Huang and Q. Wang.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.tranon.2020.100797. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

National Institutes of Health

Places

North America
United States
Americas
Ohio
Columbus

Subjects

Science and Technology
      Scientific Research
            Medical Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research